Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico , shared a post on X:
“Real-world data, 1323 pts w/EGFRm NSCLC received 1L osimertinib: mOS 28.6 mo (< FLAURA trial)
18% reached 5-y survival; 29% died before 2L, 4% had no further therapy and 19% remained on 1L
Findings support need for optimized 1L combos in high-risk pts.”
Title: Overall Survival in EGFR-mutant Advanced Non-Small Cell Lung Cancer Treated with First-line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States
Authors: Joshua K. Sabaria, Helena A. Yub, Parthiv J. Mahadeviac, Yanfang Liud , Levon Demirdjiane, Yen Hua Chend, Xiayi Wangf, Antonio Passaro.
You can read the Full Article on Journal of Thoracic Oncology.
More posts featuring Oscar Tahuahua.